In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s GILD Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or want PrEP.Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative.The first PrEP medication, which was al ...

7月25日，吉利德中国宣布，全球同类首创、一年仅需给药两次的HIV(艾滋病毒)暴露前预防药物 Lenacapavir(来那帕韦)正式落地海南博鳌乐城国际医疗旅游先行区。今年6月份，这款预防药物已获批 在美国上市，作为暴露前预防用于降低成人和体重至少35公斤青少年经性传播感染HIV的风险。(第一 财经) ...